Practical guidelines for the use of long-acting injectable second-generation antipsychotics

被引：13

作者：

Jarema, Marek ^{[1
]}

Wichniak, Adam ^{[1
]}

Dudek, Dominika ^{[2
]}

Samochowiec, Jerzy ^{[3
]}

Bienkowski, Przemyslaw ^{[4
]}

Rybakowski, Janusz ^{[5
]}

机构：

[1] III Psychiat Clin, Inst Psychiat & Neurol Warsaw, PL-02957 Warsaw, Poland

[2] Jagiellonian Univ, Coll Med, Chair Psychiat, Dept Affect Disorders, PL-31007 Krakow, Poland

[3] Pomeranian Med Univ, Dept Psychiat, Szczecin, Poland

[4] Inst Psychiat & Neurol, Dept Pharmacol, Warsaw, Poland

[5] Poznan Univ Med Sci, Dept Adult Psychiat, Poznan, Poland

来源：

PSYCHIATRIA POLSKA | 2015年 / 49卷 / 02期

关键词：

schizophrenia; long-acting antipsychotics; arpiprazole; olanzapine; paliperidone; risperidone; guidelines for use; DOUBLE-BLIND; SCHIZOPHRENIA; ARIPIPRAZOLE; DRUGS; HOSPITALIZATION; FORMULATIONS; OUTCOMES; DEPOT;

D O I：

10.12740/PP/39370

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Long-acting injectable antipsychotics constitute a valuable alternative for the treatment of psychotic disorders, mainly schizophrenia. They assure a more stable drug level, improve treatment compliance, and increase the chances for favorable and long-lasting improvement. Additionally, the long-acting second-generation antipsychotics combine the values of long-acting injectable drugs with the values of atypical antipsychotics. Four second generation long-acting antipsychotics have been described: risperidone, olanzapine, aripiprazole and paliperidone. The indications for their use, treatment strategy, tolerance, and potential interactions are discussed.

引用

页码：225 / 241

页数：17

共 50 条

[1] New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia
Citrome, Leslie
EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (07) : 767 - 783
[2] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Jann, Michael W.
Penzak, Scott R.
CNS DRUGS, 2018, 32 (03) : 241 - 257
[3] Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Michael W. Jann
Scott R. Penzak
CNS Drugs, 2018, 32 : 241 - 257
[4] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
Lik Hang N. Lee
Charles Choi
Abby C. Collier
Alasdair M. Barr
William G. Honer
Ric M. Procyshyn
CNS Drugs, 2015, 29 : 975 - 983
[5] The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
Lee, Lik Hang N.
Choi, Charles
Collier, Abby C.
Barr, Alasdair M.
Honer, William G.
Procyshyn, Ric M.
CNS DRUGS, 2015, 29 (12) : 975 - 983
[6] Guidelines for the use of long-acting injectable atypical antipsychotics
不详
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (01) : 120 - 131
[7] Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics
Pompili, Maurizio
FRONTIERS IN PSYCHIATRY, 2020, 10
[8] Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents
Michael W. Jann
Scott R. Penzak
CNS Drugs, 2018, 32 : 603 - 603
[9] Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
Montemagni, Cristiana
Frieri, Tiziana
Rocca, Paola
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2016, 12 : 917 - 929
[10] Long-acting injectable antipsychotics in the elderly - Guidelines for effective use
Masand, PS
Gupta, S
DRUGS & AGING, 2003, 20 (15) : 1099 - 1110

← 1 2 3 4 5 →